Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Oritavancin

(Orbactiv®)

Orbactiv®

Drug updated on 11/1/2024

Dosage FormInjection (intravenous: 400 mg)
Drug ClassLipoglycopeptide antibacterials
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of five systematic review(s)/meta-analysis(es). [1-5]
  • Clinical Cure and Improvement with Oritavancin (ORI): In a systematic review of 301 cases treated with multidose oritavancin (ORI), clinical cure was achieved in 85% (231/272) of patients, and clinical improvement was noted in an additional 8% (22/272) of patients, with most cases involving infections such as osteomyelitis, ABSSSI (acute bacterial skin and skin structure infections), and cellulitis.
  • Non-Inferiority in ABSSSI Treatment: Meta-analysis findings demonstrated that ORI was statistically non-inferior to control agents in efficacy outcomes for acute bacterial skin and skin structure infections (ABSSSIs), including investigator-assessed clinical cure and lesion size reduction, positioning it as a viable alternative to standard treatments.
  • Adverse Events with Oritavancin: In a systematic review, the most common adverse events for patients treated with oritavancin included infusion-related reactions and hypoglycemia. Oritavancin was generally well-tolerated, showing a favorable safety profile across various infections.
  • Comparison to Vancomycin: Oritavancin was associated with significantly fewer adverse events than vancomycin (RR = 0.72; P < 0.01) and showed similar all-cause mortality rates, highlighting a potential advantage in tolerability for treating Gram-positive infections.
  • Population Types and Specific Infections Treated: The systematic review identified the most common infections treated with oritavancin as osteomyelitis (148 cases), ABSSSI (35 cases), and cellulitis (14 cases), primarily involving MRSA (Methicillin-resistant Staphylococcus aureus) (121 cases) and MSSA (66 cases), with additional isolates of CoNS, E. faecalis, and E. faecium.
  • Subgroup Findings in ABSSSI: In a meta-analysis of ABSSSI treatment, oritavancin significantly reduced the rate of 30-day emergency room visits in outpatient settings (RR = 0.34; P < 0.00001), indicating potential benefits for managing ABSSSI in outpatient care.